Resources

Aged care assessors can print this document and give it to older people during assessments. It provides information for older people about My Aged Care support plans, My Health Record, sharing support plans with My Health Record, key contacts and useful links.

This document provides information for healthcare providers about My Aged Care support plans being available in My Health Record.

The ATAGI 2024 Annual Statement on Immunisation is the fourth publication in this series. The statement highlights the key successes, trends and challenges in the use of vaccines and control of vaccine preventable diseases in Australia in 2023, and includes advice to address key issues for 2024.

These guidelines contain the general, initial and ongoing eligibility requirements to access certain medications for Gaucher disease (type 1) under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for hereditary tyrosinaemia (type 1) under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for late-infantile onset Batten disease under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for infantile-onset or late-onset Pompe disease under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type I (MPS I) under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type II (MPS II) under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type IVA (MPS IVA) under the Life Saving Drugs Program.

These guidelines contain the general, initial and ongoing eligibility requirements to access treatment for mucopolysaccharidosis type VI (MPS VI) under the Life Saving Drugs Program.

Treating physicians use this application form to apply for a patient to access LSDP medication for Batten disease for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for Gaucher disease for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for hereditary tyrosinaemia (type 1) for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for Pompe disease for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS I for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS II for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS IVA for the first time, or after a break.

Treating physicians use this application form to apply for a patient to access LSDP medication for MPS VI for the first time, or after a break.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Gaucher disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for hereditary tyrosinaemia (type 1).

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Batten disease.

Treating physicians use this form to reapply each year for a patient to receive ongoing LSDP medication for Pompe disease.